临床实践中肺癌筛查中 Lung-RADS 3 类和 4 类结节的癌症频率
该回顾性研究基于 2014 年 6 月至 2021 年 1 月共 9148 次低剂量 CT 肺癌筛查检查(4798 例患者),分析临床实践中归为 Lung-RADS 3 或 4 类的 1297 个结节的恶性频率。结果显示 3、4A、4B、4X 类结节的恶性频率分别为 3.9%、15.5%、36.3%、76.8%,均高于 Lung-RADS 推荐及既往回顾性分类研究的估计值;45/46(97.8%)的支气管内 4A 类结节为良性。
要点
- 临床实践中 Lung-RADS 3 和 4 类结节的恶性频率高于指南估计值。
- 4X 类结节恶性频率 76.8%,4B 为 36.3%,4A 为 15.5%,3 类为 3.9%。
- 支气管内 4A 类结节 97.8%(45/46)为良性,可能为炎性/黏液栓所致。
核心结论
- 在肺癌筛查临床实践中应用 Lung-RADS 时,3 类和 4 类结节的频率及其中癌症频率均高于 Lung-RADS 推荐和既往回顾性分类研究的估计值;几乎所有支气管内 4A 类结节为良性。
研究设计与样本
- 回顾性研究,基于 2014年6月至2021年1月 共 9148 次连续低剂量 CT 肺癌筛查检查(4798 例患者)的临床放射学报告,由多学科会议结合组织学分析和随访影像判定结节良性或恶性,良性诊断需至少 12 个月随访影像稳定。
关键影像表现/征象
- 最终分析纳入 1139 例患者的 1297 个独特结节(男 598 例,女 541 例;平均年龄 66.0 ± 6.3 岁)。
- 实性结节恶性频率 13.1%,部分实性结节 24.4%,磨玻璃结节 13.5%。
- 46 个支气管内结节(均为 4A 类)中 45 个(97.8%)基于吸收消散判定为良性。
诊断标准与关键数值
- 3 类结节恶性频率 3.9%。
- 4A 类结节恶性频率 15.5%。
- 4B 类结节恶性频率 36.3%。
- 4X 类结节恶性频率 76.8%。
- 全部 1297 个结节中良性 1108 个(85.4%),恶性 189 个(14.6%)。
临床应用与阅片要点
- 临床实践中 Lung-RADS 3 和 4 类结节的实际恶性风险高于指南估计,阅片和报告时应结合患者具体情况审慎评估。
- 对于支气管内 4A 类结节,若形态符合黏液栓或炎性改变,可考虑短期随访观察其吸收消散。
局限性
- 本研究为回顾性研究。
- 研究基于单中心建立的肺癌筛查项目。
- 原文指出未来 Lung-RADS 版本应考虑本真实世界研究结果以提高系统临床效用,但未明确使用「需进一步研究」等措辞。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Lung-RADS category 3 and 4 nodules account for most screening-detected lung cancers and are considered actionable nodules with management implications. The cancer frequency among such nodules is estimated in the Lung-RADS recommendations and has been investigated primarily by means of retrospectively assigned Lung-RADS classifications. OBJECTIVE. The purpose of this study was to assess the frequency of cancer among lung nodules assigned Lung-RADS category 3 or 4 at lung cancer screening (LCS) in clinical practice and to evaluate factors that affect the cancer frequency within each category. METHODS. This retrospective study was based on review of clinical radiology reports of 9148 consecutive low-dose CT LCS examinations performed for 4798 patients between June 2014 and January 2021 as part of an established LCS program. Unique nodules assigned Lung-RADS category 3 or 4 (4A, 4B, or 4X) that were clinically categorized as benign or malignant in a multidisciplinary conference that considered histologic analysis and follow-up imaging were selected for further analysis. Benign diagnoses based on stability required at least 12 months of follow-up imaging. Indeterminate nodules were excluded. Cancer frequencies were evaluated. RESULTS. Of the 9148 LCS examinations, 857 (9.4%) were assigned Lung-RADS category 3, and 721 (7.9%) were assigned category 4. The final analysis included 1297 unique nodules in 1139 patients (598 men, 541 women; mean age, 66.0 ± 6.3 years). A total of 1108 of 1297 (85.4%) nodules were deemed benign, and 189 of 1297 (14.6%) were deemed malignant. The frequencies of malignancy of category 3, 4A, 4B, and 4X nodules were 3.9%, 15.5%, 36.3%, and 76.8%. A total of 45 of 46 (97.8%) endobronchial nodules (all category 4A) were deemed benign on the basis of resolution. Cancer frequency was 13.1% for solid, 24.4% for part-solid, and 13.5% for ground-glass nodules. CONCLUSION. In the application of Lung-RADS to LCS clinical practice, the frequency of Lung-RADS category 3 and 4 nodules and the cancer frequency in these categories were higher than the prevalence and cancer risk estimated for category 3 and 4 nodules in the Lung-RADS recommendations and those reported in earlier studies in which category assignments were retrospective. Nearly all endobronchial category 4A nodules were benign. CLINICAL IMPACT. Future Lung-RADS iterations should consider the findings of this study from real-world practice to improve the clinical utility of the system.
引用
- Mendoza, Petranovic, Som, et al. Lung-RADS Category 3 and 4 Nodules on Lung Cancer Screening in Clinical Practice. AJR Am J Roentgenol. 2022. PMID: 35080453. doi:10.2214/AJR.21.27180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。